Related references
Note: Only part of the references are listed.Diagnosis and Treatment of Parkinson Disease A Review
Melissa J. Armstrong et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)
Apomorphine sublingual film for off episodes in Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 study
C. Warren Olanow et al.
LANCET NEUROLOGY (2020)
Inhaled levodopa in Parkinson's disease patients with OFF periods: A randomized 12-month pulmonary safety study
Donald G. Grosset et al.
PARKINSONISM & RELATED DISORDERS (2020)
Continuous Dopaminergic Stimulation as a Treatment for Parkinson's Disease: Current Status and Future Opportunities
C. Warren Olanow et al.
MOVEMENT DISORDERS (2020)
Safety and efficacy of CVT-301 (levodopa inhalation powder) on motor function during off periods in patients with Parkinson's disease: a randomised, double-blind, placebocontrolled phase 3 trial (vol 18, pg 145, 2019)
P. A. LeWitt et al.
LANCET NEUROLOGY (2019)
CVT-301 for Parkinson's disease: dose and effect size issues
Olivier Rascol
LANCET NEUROLOGY (2019)
Orally inhaled levodopa (CVT-301) for early morning OFF periods in Parkinson's disease
Robert A. Hauser et al.
PARKINSONISM & RELATED DISORDERS (2019)
Apomorphine for Parkinson's Disease: Efficacy and Safety of Current and New Formulations
Federico Carbone et al.
CNS DRUGS (2019)
Safety and efficacy of CVT-301 (levodopa inhalation powder) on motor function during off periods in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 trial
Peter A. LeWitt et al.
LANCET NEUROLOGY (2019)
Levodopa: A New Look at An Old Friend
C. Warren Olanow et al.
MOVEMENT DISORDERS (2018)
Challenges and trends in apomorphine drug delivery systems for the treatment of Parkinson's disease
Nrupa Borkar et al.
ASIAN JOURNAL OF PHARMACEUTICAL SCIENCES (2018)
International Parkinson and Movement Disorder Society Evidence-Based Medicine Review: Update on Treatments for the Motor Symptoms of Parkinson's Disease
Susan H. Fox et al.
MOVEMENT DISORDERS (2018)
The spectrum of off in Parkinson's disease: What have we learned over 40 years?
Kelvin L. Chou et al.
PARKINSONISM & RELATED DISORDERS (2018)
Apomorphine subcutaneous infusion in patients with Parkinson's disease with persistent motor fluctuations (TOLEDO): a multicentre, double-blind, randomised, placebo-controlled trial
Regina Katzenschlager et al.
LANCET NEUROLOGY (2018)
The Skin and Parkinson's Disease: Review of Clinical, Diagnostic, and Therapeutic Issues
Matej Skorvanek et al.
MOVEMENT DISORDERS CLINICAL PRACTICE (2017)
A randomized trial of inhaled levodopa (CVT-301) for motor fluctuations in Parkinson's disease
Peter A. LeWitt et al.
MOVEMENT DISORDERS (2016)
The hidden sister of motor fluctuations in Parkinson's disease: A review on nonmotor fluctuations
Raul Martinez-Fernandez et al.
MOVEMENT DISORDERS (2016)
Sublingual apomorphine (APL-130277) for the acute conversion of OFF to ON in Parkinson's disease
Robert A. Hauser et al.
MOVEMENT DISORDERS (2016)
The efficacy of apomorphine - A non-motor perspective
Miguel Rosa-Grilo et al.
PARKINSONISM & RELATED DISORDERS (2016)
Preclinical and clinical assessment of inhaled levodopa for OFF episodes in Parkinson's disease
Michael M. Lipp et al.
SCIENCE TRANSLATIONAL MEDICINE (2016)
Buccal mucosal irritation studies of sublingual apomorphine film (APL-130277) in Syrian golden hamsters
Thierry Bilbault et al.
THERAPEUTIC DELIVERY (2016)
Infusion Therapies and Development of Impulse Control Disorders in Advanced Parkinson Disease: Clinical Experience After 3 Years' Follow-up
Antoniya Todorova et al.
CLINICAL NEUROPHARMACOLOGY (2015)
A Randomized Controlled Trial of Subcutaneous Apomorphine for Parkinson Disease: A Repeat Dose and Pharmacokinetic Study
Masahiro Nomoto et al.
CLINICAL NEUROPHARMACOLOGY (2015)
Levodopa Therapy for Parkinson's Disease: Pharmacokinetics and Pharmacodynamics
Peter A. LeWitt
MOVEMENT DISORDERS (2015)
for the LCIG Horizon Study Group. Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy study (vol 13, pg 141, 2014)
C. W. Olen et al.
LANCET NEUROLOGY (2014)
Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy study
C. Warren Olanow et al.
LANCET NEUROLOGY (2014)
Phase IIa randomized double-blind, placebo-controlled study of inhaled apomorphine as acute challenge for rescuing 'off' periods in patients with established Parkinson's disease
K. A. Grosset et al.
EUROPEAN JOURNAL OF NEUROLOGY (2013)
Factors predictive of the development of Levodopa-induced dyskinesia and wearing-off in Parkinson's disease
C. Warren Olanow et al.
MOVEMENT DISORDERS (2013)
Enhancement of transdermal apomorphine delivery with a diester prodrug strategy
Kuo-Sheng Liu et al.
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS (2011)
Meta-Analysis of the Comparative Efficacy and Safety of Adjuvant Treatment to Levodopa in Later Parkinson's Disease
Rebecca Stowe et al.
MOVEMENT DISORDERS (2011)
Initiating Levodopa/Carbidopa Therapy With and Without Entacapone in Early Parkinson Disease The STRIDE-PD Study
Fabrizio Stocchi et al.
ANNALS OF NEUROLOGY (2010)
Clinical Experiences With Levodopa Methylester (Melevodopa) in Patients With Parkinson Disease Experiencing Motor Fluctuations: An Open-Label Observational Study
Roberta Zangaglia et al.
CLINICAL NEUROPHARMACOLOGY (2010)
When Do Levodopa Motor Fluctuations First Appear in Parkinson's Disease?
Fabrizio Stocchi et al.
EUROPEAN NEUROLOGY (2010)
Patient perception of dyskinesia in Parkinson's disease
S. W. Hung et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2010)
The scientific and clinical basis for the treatment of Parkinson disease (2009)
C. Warren Olanow et al.
NEUROLOGY (2009)
Effect of low concentrations of apomorphine on parkinsonism in a randomized, placebo-controlled, crossover study
Steven A. Gunzler et al.
ARCHIVES OF NEUROLOGY (2008)
Subcutaneous apomorphine in patients with advanced Parkinson's disease: A dose-escalation study with randomized, double-blind, placebo-controlled crossover evaluation of a single dose
Rajesh Pahwa et al.
JOURNAL OF THE NEUROLOGICAL SCIENCES (2007)
Continued efficacy and safety of subcutaneous apomorphine in patients with advanced Parkinson's disease
Ronald F. Pfeiffer et al.
PARKINSONISM & RELATED DISORDERS (2007)
Continuous dopamine-receptor treatment of Parkinson's disease: scientific rationale and clinical implications
C. Warren Olanow et al.
LANCET NEUROLOGY (2006)
Early administration of entacapone prevents levodopa-induced motor fluctuations in hemiparkinsonian rats
C Marin et al.
EXPERIMENTAL NEUROLOGY (2005)
Sydney multicenter study of Parkinson's disease: non-L-dopa-responsive problems dominate at 15 years
MA Hely et al.
MOVEMENT DISORDERS (2005)
Impact of the motor complications of Parkinson's disease on the quality of life
S Chapuis et al.
MOVEMENT DISORDERS (2005)
Levodopa pharmacokinetics and motor performance during activities of daily living in patients with Parkinson's disease on individual drug combinations
D Nyholm et al.
CLINICAL NEUROPHARMACOLOGY (2002)
Deep-brain stimulation of the subthalamic nucleus or the pars interna of the globus pallidus in Parkinson's disease.
JA Obeso et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
A randomized, double-blind, placebo-controlled trial of subcutaneously injected apomorphine for Parkinsonian off-state events
RB Dewey et al.
ARCHIVES OF NEUROLOGY (2001)
Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature
JE Ahlskog et al.
MOVEMENT DISORDERS (2001)
Intravenous apomorphine therapy in Parkinson's disease - Clinical and pharmacokinetic observations
AJ Manson et al.
BRAIN (2001)
Dyskinesias and motor fluctuations in Parkinson's disease - A community-based study
A Schrag et al.
BRAIN (2000)
Pathophysiology of the basal ganglia in Parkinson's disease
JA Obeso et al.
TRENDS IN NEUROSCIENCES (2000)